Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHMT2 | P34897 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 6/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.37 |
| ▸ | AURKA | O14965 | 5/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 3/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.37 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | BLK | P51451 | 2/20 | 0.37 |
| ▸ | STK3 | Q13188 | 2/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744085 | 0.92 | FGFR1 (0.46) | FLT3KDRKITFGFR1AURKB | |
| SCHEMBL742347 | 0.91 | MAPK14 (0.40) | FLT3KDRKITFGFR1AURKB | |
| SCHEMBL744854 | 0.90 | FLT3 (0.38) | FLT3KDRKITFGFR1AURKB | |
| SCHEMBL744362 | 0.90 | RAB9A (0.40) | FLT3KDRKITAURKBAURKA | |
| Bromide SCHEMBL741865 | 0.89 | FLT3 (0.38) | FLT3KDRKITFGFR1AURKB | |
| Hydrochloric Acid SCHEMBL744245 | 0.89 | FLT3 (0.38) | FLT3KDRKITFGFR1AURKB | |
| SCHEMBL743410 | 0.89 | ATM (0.39) | FLT3KDRKITFGFR1AURKB | |
| SCHEMBL743943 | 0.88 | FLT3 (0.39) | FLT3KDRKITFGFR1AURKB | |
| SCHEMBL15221976 | 0.88 | AURKB (0.46) | SHMT2FLT3KDRKITFGFR1 | |
| SCHEMBL746492 | 0.88 | RAB9A (0.41) | FLT3KDRKITFGFR1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | claimed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | claimed |
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138336-B2 | Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase | BAYER HEALTHCARE LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC | 2010-10-28 | — | — | US | disclosed |
| EP-2203060-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | Bayer Healthcare, LLC (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009042543-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | BAYER HEALTHCARE LLC (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273800-A1 | PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE | AURKC, AURKA, PLK1 | SHMT2 572/4885FLT3 379/4885KDR 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.